> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Contradictory Info in P&G Nyquil Filing: FDA
- URL: https://www.fdaweb.com/contradictory-info-in-p-g-nyquil-filing-fda/
- Published: 2023-03-22T12:00:00.000Z
- Updated: 2026-09-14T18:21:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154040

FDA says its review of the Procter & Gamble drug listing information for its Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion determined that there is contradictory information between the labeling and the electronic listing file. A 3/14 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/procter-gamble-manufactura-s-de-rl-de-cv-650837-03142023?ref=fdaweb.com) refers the company to a 10/31/22 drug listing deficiency letter notification describing the deficiencies in the submitted information. It also cites an agency 12/15/22 e-mail stating that the continued deficiencies resulted in the product’s data removal from the FDA Online NDC (National Drug Code) Directory.

Procter & Gamble was told to respond with a list of specific actions it has taken to correct the violations and prevent their recurrence, with copies of related documentation and a schedule for completing the corrections.